Oxford Biomedica PLC Logo

Oxford Biomedica PLC

A CDMO for cell & gene therapy, providing end-to-end viral vector development & manufacturing.

OXB | IL

Overview

Corporate Details

ISIN(s):
GB00BDFBVT43
LEI:
213800S1GVQNXQ15K851
Country:
United Kingdom
Address:
WINDRUSH COURT, OX4 6LT OXFORD
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Oxford Biomedica PLC (OXB) is a global, innovation-led contract development and manufacturing organization (CDMO) specializing in cell and gene therapy. As a pioneer with over 30 years of experience, the company provides end-to-end services for the development and GMP manufacturing of viral vectors, including lentivirus, adeno-associated virus (AAV), and adenovirus. OXB supports pharmaceutical and biotechnology clients, from early-stage development to commercialization, through its global network of facilities in the UK, US, and France. The company leverages proprietary technology platforms, such as its commercially approved LentiVector™ and inAAVate™ systems, to enable the delivery of life-changing therapies.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-10-01 08:00
Declaration of Voting Results & Voting Rights Announcements
Total Voting Rights
English 11.6 KB
2025-09-23 08:00
Earnings Release
Interim Results for 6 months ended 30 June 2025
English 732.3 KB
2025-08-22 16:36
Director's Dealing
PDMR Dealings
English 29.1 KB
2025-08-21 11:24
Major Shareholding Notification
Holding(s) in Company
English 22.2 KB
2025-08-20 08:00
Declaration of Voting Results & Voting Rights Announcements
Admission of Shares and Total Voting Rights
English 10.9 KB
2025-08-15 14:45
Director's Dealing
PDMR Dealings
English 18.8 KB
2025-08-15 08:05
Share Issue/Capital Change
Results of Placing
English 43.5 KB
2025-08-14 18:02
Share Issue/Capital Change
Proposed Placing of New Ordinary Shares
English 168.6 KB
2025-08-01 08:00
Capital/Financing Update
OXB Secures New Loan Facility with Oaktree
English 16.3 KB
2025-08-01 08:00
Declaration of Voting Results & Voting Rights Announcements
Total Voting Rights
English 10.9 KB
2025-07-28 08:00
Earnings Release
Half Year Trading Update
English 23.8 KB
2025-07-02 08:00
Board/Management Information
Director Declaration
English 9.6 KB
2025-06-23 08:00
M&A Activity
OXB completes acquisition of US subsidiary
English 12.3 KB
2025-06-17 19:00
Director's Dealing
Director/PDMR Shareholding
English 18.8 KB
2025-06-11 08:02
Pre-Annual General Meeting Information
AGM Update
English 12.6 KB

Automate Your Workflow. Get a real-time feed of all Oxford Biomedica PLC filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Oxford Biomedica PLC via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Fine Foods & Pharmaceuticals Ntm Logo
Contract development & manufacturing of oral solids for pharma, nutraceutical & cosmetic sectors.
Italy FF
Formycon AG Logo
Develops cost-effective biosimilars for ophthalmology, immunology, and other chronic diseases.
Germany FYB
Friulchem Logo
CDMO for animal health, providing vet pharma & supplement solutions for pets and livestock.
Italy FCM
Fuji Pharma Co.,Ltd. Logo
Specializes in hormone medicines for ob/gyn, injectables, and contract manufacturing.
Japan 4554
Fuso Pharmaceutical Industries,Ltd. Logo
Manufactures essential pharmaceuticals like dialysis drugs, infusions, and injections for healthcare.
Japan 4538
FutureChem Co., Ltd. Logo
Develops radiopharmaceuticals & diagnostic agents for cancer, Alzheimer's, and Parkinson's disease.
South Korea 220100
Future Medicine  Co., Ltd. Logo
Clinical-stage biopharma developing novel synthetic drugs for inflammation, fibrosis, and oncology.
South Korea 341170
Develops long-acting injectable therapies for chronic diseases and cancer.
South Korea 456160
Gabather AB Logo
Developing novel GABAA receptor drugs for neuropsychiatric disorders.
Sweden GABA
Galapagos NV Logo
Biotech firm developing novel CAR-T cell therapies for oncology via a rapid delivery platform.
Belgium GLPG

Talk to a Data Expert

Have a question? We'll get back to you promptly.